ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday, ValuEngine reports.

ANIP has been the topic of a number of other research reports. Guggenheim began coverage on shares of ANI Pharmaceuticals in a research note on Thursday, September 12th. They issued a “buy” rating and a $76.00 price target on the stock. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 22nd. Finally, Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of “Buy” and an average price target of $85.00.

Shares of NASDAQ:ANIP traded down $4.05 during trading on Thursday, hitting $57.38. 388,900 shares of the company’s stock were exchanged, compared to its average volume of 137,916. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $86.96. The firm has a 50-day moving average price of $73.65 and a two-hundred day moving average price of $73.58. The firm has a market cap of $954.49 million, a P/E ratio of 12.45 and a beta of 2.20.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $56.10 million. During the same period in the previous year, the firm posted $1.29 EPS. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals will post 5.29 EPS for the current year.

In other news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $68.21, for a total value of $516,963.59. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders sold 78,591 shares of company stock worth $5,582,839. 24.70% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in ANIP. First Trust Advisors LP lifted its position in shares of ANI Pharmaceuticals by 1.2% in the first quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock worth $1,067,000 after purchasing an additional 179 shares in the last quarter. WINTON GROUP Ltd raised its position in ANI Pharmaceuticals by 80.5% during the second quarter. WINTON GROUP Ltd now owns 7,868 shares of the specialty pharmaceutical company’s stock worth $647,000 after acquiring an additional 3,509 shares in the last quarter. Truvestments Capital LLC raised its position in ANI Pharmaceuticals by 14.2% during the second quarter. Truvestments Capital LLC now owns 2,261 shares of the specialty pharmaceutical company’s stock worth $186,000 after acquiring an additional 281 shares in the last quarter. Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in ANI Pharmaceuticals during the second quarter worth $1,069,000. Finally, New York State Teachers Retirement System raised its position in ANI Pharmaceuticals by 1.8% during the second quarter. New York State Teachers Retirement System now owns 25,280 shares of the specialty pharmaceutical company’s stock worth $2,078,000 after acquiring an additional 452 shares in the last quarter. 70.97% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: Consumer Price Index (CPI)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.